S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   122.85 (+0.11%)
MSFT   214.17 (-0.94%)
FB   287.96 (+0.49%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,204.57 (-0.48%)
TSLA   560.67 (-4.12%)
NVDA   541.50 (+1.10%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.35 (+1.97%)
MU   68.49 (+2.10%)
AMD   93.58 (+1.03%)
T   28.94 (+0.24%)
NIO   47.14 (+3.92%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.66 (-0.38%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.60 (+2.11%)
S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   122.85 (+0.11%)
MSFT   214.17 (-0.94%)
FB   287.96 (+0.49%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,204.57 (-0.48%)
TSLA   560.67 (-4.12%)
NVDA   541.50 (+1.10%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.35 (+1.97%)
MU   68.49 (+2.10%)
AMD   93.58 (+1.03%)
T   28.94 (+0.24%)
NIO   47.14 (+3.92%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.66 (-0.38%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.60 (+2.11%)
S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   122.85 (+0.11%)
MSFT   214.17 (-0.94%)
FB   287.96 (+0.49%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,204.57 (-0.48%)
TSLA   560.67 (-4.12%)
NVDA   541.50 (+1.10%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.35 (+1.97%)
MU   68.49 (+2.10%)
AMD   93.58 (+1.03%)
T   28.94 (+0.24%)
NIO   47.14 (+3.92%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.66 (-0.38%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.60 (+2.11%)
S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   122.85 (+0.11%)
MSFT   214.17 (-0.94%)
FB   287.96 (+0.49%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,204.57 (-0.48%)
TSLA   560.67 (-4.12%)
NVDA   541.50 (+1.10%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.35 (+1.97%)
MU   68.49 (+2.10%)
AMD   93.58 (+1.03%)
T   28.94 (+0.24%)
NIO   47.14 (+3.92%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.66 (-0.38%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.60 (+2.11%)
Log in
ARCA:NBY

NovaBay Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.12 million shs
Market Capitalization$25.36 million
P/E RatioN/A
Dividend YieldN/A
Beta3.96
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone510 899 8800
Employees26

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.60 million
Book Value$0.03 per share

Profitability

Net Income$-9,650,000.00

Miscellaneous

Market Cap$25.36 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NovaBay Pharmaceuticals (ARCA:NBY) Frequently Asked Questions

What stocks does MarketBeat like better than NovaBay Pharmaceuticals?

Wall Street analysts have given NovaBay Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovaBay Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of NovaBay Pharmaceuticals' key competitors?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:
  • Mr. Justin M. Hall Esq., Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director (Age 42, Pay $325.72k)
  • Mr. Andrew D. Jones, CFO & Treasurer
  • Ms. Wang Xu, Sr. Mang. & Controller (Age 37)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the ARCA under the ticker symbol "NBY."

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $0.00 and generates $6.60 million in revenue each year. The company earns $-9,650,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. NovaBay Pharmaceuticals employs 26 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is www.novabay.com.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 POWELL STREET SUITE 1150, EMERYVILLE CA, 94608. The company can be reached via phone at 510 899 8800 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.